HCM - Hutchison China MediTech / Chi-Med

-

$undefined

N/A

(N/A)

Hutchison China MediTech / Chi-Med NasdaqGS:HCM HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Location: Cheung Kong Center, Hong Kong, Hong Kong | Website: https://www.hutch-med.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

11.11B

Cash

838.8M

Avg Qtr Burn

N/A

Short % of Float

0.09%

Insider Ownership

0.13%

Institutional Own.

3.87%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details
Colorectal cancer , Metastatic colorectal cancer, Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

ORPATHYS (Savolitinib) Details
Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer

Approved

Quarterly sales

HMPL-306 Details
Hematologic malignancies, Blood cancer, Acute myeloid leukemia

Phase 3

Data readout

ORPATHYS (Savolitinib) (C-MET inhibitor) Details
Renal cell carcinoma, Cancer, Gastric cancer

Phase 3

Data readout

ORPATHYS (Savolitinib) + osimertinib Details
EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced Non-small cell lung carcinoma

Phase 3

Data readout

Phase 3

Data readout

SULANDA (Surufatinib) Details
Solid tumor/s, Neuroendocrine tumor, Pancreatic cancer, Cholangiocarcinoma, Cancer

Phase 3

Update

ELUNATE (Fruquintinib) + paclitaxel Details
Cancer, Solid tumor/s, Gastroesophageal adenocarcinomas, Gastric cancer

Phase 3

Update

SULANDA (Surufatinib) + Camrelizumab Details
Solid tumor/s, Pancreatic cancer, Cancer, Pancreatic ductal adenocarcinoma

Phase 2/3

Data readout

ELUNATE (Fruquintinib) + Sintilimab Details
Solid tumor/s, Renal cell carcinoma, Cancer, Kidney cancer

Phase 2/3

Update

Sovleplenib (HMPL-523) (Syk inhibitor) Details
Warm autoimmune hemolytic anemia

Phase 2/3

Update

ORPATHYS (Savolitinib) + TAGRISSO Details
Non-small cell lung carcinoma, Cancer

Phase 2

Data readout

Tazemetostat Details
Follicular lymphoma

Phase 2

Data readout

Phase 2

Update

HMPL-453 (FGFR 1/2/3) Details
Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer

Phase 2

Update

Sovleplenib (HMPL-523) (Syk inhibitor) Details
Warm autoimmune hemolytic anemia

Phase 1/2

Update

ELUNATE (Fruquintinib) + Sintilimab Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Update

Phase 1/2

Initiation

HMPL-506 Details
Cancer, Leukemia

Phase 1

Data readout